Approvals/Requirements Satisfied by eRADIMAGING Courses
- ASRT approval for ARRT Category A credit
- All Courses eligible of international radiographers' CPD requirements
- ASRT and MDCB are approved continuing education providers of ARRT and all courses are accepted by ARRT
- California CE requirements met for all radiography courses
- NMTCB accepted (All Courses)
- All Courses available for RRAs
- ARMRIT accepted (All MRI Courses)
- MDCB approval by the Medical Dosimetrist Certification (Selected Courses)
- Florida approval for all courses 1 credit or more
- ARDMS accepted (All Courses)
- CAMRT and Sonography Canada recognize the ASRT approval (All Courses)
- Approval: This course is approved by MDCB - an approved continuing education provider of ARRT.
- Release Date: 2/4/2021
- Expiration Date: 2/4/2022
- Credit Hours: 1 Credit
-
Course Description and objectives:
Course Description
Non-Hodgkin lymphoma (NHL) is currently the second fastest rising cancer in the United States, with a doubling in incidence over the last 30 years. In addition to more conventional therapy for NHL with chemotherapy, external beam radiation therapy, bone marrow or stem cell transplantation, or a combination of these strategies, radioimmunotherapy (RIT) has been introduced during the past decade and represents a promising therapeutic strategy in patients with B-cell NHL. However, the safe and effective delivery of RIT for NHL requires advanced coordination of care between diverse members of the patient's clinical team, including the nuclear medicine physician, medical oncologist, radiation oncologist, as well as nurses, pharmacists and radiologic technologists. Consequently, radiologic technologists and other professionals responsible for these patients require an understanding of NHL disease, in addition to knowledge of the important operating parameters and safety issues surrounding RIT in these patients. This article will review the signs and symptoms, diagnosis, staging, and treatment options for NHL, with a focus on B-cell NHL. In addition, current options for RIT will be reviewed, with special attention to initial patient evaluation and dosing, follow-up imaging, and important radiation safety concerns for patients, caregivers, family members and institutions delivering care.Learning Objectives
After reading this article, the participant should be able to:- Describe the signs and symptoms associated with non-Hodgkin lymphoma (NHL), as well as the differential diagnosis and staging of NHL disease.
- Identify currently available treatment options of B-cell NHL.
- Explain the differences between radioimmunotherapy treatment options currently available for B-cell NHL.
- Discuss the unique aspects of radioimmunotherapy treatment protocols for NHL.
- Recognize the unique operating challenges, including radiation safety issues, facing institutions that provide radioimmunotherapy treatment services.
Categories: Nuclear Medicine, Radiation Therapy
-
CE Information:
In order to receive CE credit, you must first complete the activity content. When completed, go to the "Take CE Test!" link to access the post-test.
Submit the completed answers to determine if you have passed the post-test assessment. You must obtain a score of 75% to receive the CE credit. You will have no more than 3 attempts to successfully complete the post-test.
Participants successfully completing the activity content and passing the post-test will receive 1.0 ARRT Category A credits.
Approved by the American Society of Radiologic Technologists for ARRT Category A credit.
Approved by the Medical Dosimetrist Certification Board for MDCB credit.
This activity may be available in multiple formats or from different sponsors. ARRT does not allow CE activities such as Internet courses, home study programs, or directed readings to be repeated for CE credit in the same or any subsequent biennium.
-
Structured Education Credit Valuations:
Category Content Area Credits Nuclear Medicine Procedures 0.5 Nuclear Medicine Safety 0.25 Radiation Therapy Procedures 0.5 -
CQR Credit Valuations:
Category Subcategory Credits Nuclear Medicine Endocrine and Oncology Procedures 0.25 Nuclear Medicine Radiation Physics, Radiobiology, and Reguations 0.25 Nuclear Medicine Radionuclides and Radiopharmaceuticals 0.25 Radiation Therapy Treatment Sites and Tumors 0.5
Radioimmunotherapy: A Review of I-131 Tositumomab and Y-90 Ibritumomab Tiuxetan for the Treatment of NHL
Vesper Grantham, MEd, RT(N), CNMT, Linda Alfred, MEd, RT(T), Stacy Anderson, MS, RT(T), CMD, and Cara Argo, CNMT
*Associate Professor, Nuclear Medicine Program Director; Vice-Chairman, Department of Medical Imaging and Radiation Sciences, University of Oklahoma Health Sciences Center, College of Allied Health, Oklahoma City, Oklahoma.
†Assistant Professor, Radiation Therapy Clinical Coordinator, Department of Medical Imaging and Radiation Sciences, College of Allied Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
‡Radiation Therapy Program Director; Chair, Department of Medical Imaging and Radiation Sciences, College of Allied Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
§Nuclear Medicine Technologist; Graduate, Nuclear Medicine Technology Program, Department of Medical Imaging and Radiation Sciences, College of Allied Health, University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma.
Address correspondence to: Vesper Grantham, MEd, RT(N), Associate Professor, Nuclear Medicine Program Director; Vice-Chairman, Department of Medical Imaging and Radiation Sciences, University of Oklahoma Health Sciences Center, College of Allied Health, 1200 North Stonewall, AHB-3021, Oklahoma City, OK 73117. E-mail: Vesper-Grantham@ouhsc.edu.
Disclosures: The authors report having no significant financial or advisory relationships with corporate organizations related to this activity.
ABSTRACT
Non-Hodgkin lymphoma (NHL) is currently the second fastest rising cancer in the United States, with a doubling in incidence over the last 30 years. In addition to more conventional therapy for NHL with chemotherapy, external beam radiation therapy, bone marrow or stem cell transplantation, or a combination of these strategies, radioimmunotherapy (RIT) has been introduced during the past decade and represents a promising therapeutic strategy in patients with B-cell NHL. However, the safe and effective delivery of RIT for NHL requires advanced coordination of care between diverse members of the patient's clinical team, including the nuclear medicine physician, medical oncologist, radiation oncologist, as well as nurses, pharmacists and radiologic technologists. Consequently, radiologic technologists and other professionals responsible for these patients require an understanding of NHL disease, in addition to knowledge of the important operating parameters and safety issues surrounding RIT in these patients. This article will review the signs and symptoms, diagnosis, staging, and treatment options for NHL, with a focus on B-cell NHL. In addition, current options for RIT will be reviewed, with special attention to initial patient evaluation and dosing, follow-up imaging, and important radiation safety concerns for patients, caregivers, family members and institutions delivering care.
View the full content
Sample eRADIMAGING Course *
* This sample course is for reference purposes only. It is not currently available for earning CE credits. To earn ARRT CE credits please subscribe to eRADIMAGING where you will see a complete listing of all active and eligible CE courses.
984.227.8560Newsletter
Enter your email address to receive our new course alerts.